REG - Hemogenyx Pharma Plc - Result of Annual General Meeting

Hemogenyx PharmaceuticalsAnnouncement

30/06/2023 16:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230630:nRSd6159Ea&default-theme=true

RNS Number : 6159E  Hemogenyx Pharmaceuticals PLC  30 June 2023

30 June 2023

 

Hemogenyx Pharmaceuticals plc

("Hemogenyx Pharmaceuticals" or the "Company")

 

Result of Annual General Meeting

 

Hemogenyx Pharmaceuticals plc is pleased to announce that, at the Annual
General Meeting ("AGM") held earlier today, all resolutions were duly passed
on a show of hands. The numbers of proxy votes for each resolution submitted
prior to the meeting are presented below.

 

Proxy Voting Results

 Ordinary Resolutions                                                         Votes for    % of votes cast for  Votes Against  % of votes cast against  Total votes cast  Total votes cast as % of ISC (1)  Votes with-held (2)
 1. To adopt the 2022 Annual Report and Accounts                              187,231,295  99.86                260,529        0.14                     187,491,824       16.42                             4,905,675
 2. To approve the Directors' Remuneration Policy                             175,511,893  91.34                16,644,001     8.66                     192,155,894       16.83                             241,605
 3. To re-appoint Peter Redmond as Director                                   161,957,826  86.38                25,531,232     13.62                    187,489,058       16.42                             4,908,441
 4. To re-appoint Alexis Sandler as Director                                  175,078,447  93.44                12,285,451     6.56                     187,363,898       16.41                             5,033,601
 5. To re-appoint Dr Vladislav Sandler as Director                            175,160,284  93.49                12,203,614     6.51                     187,363,898       16.41                             5,033,601
 6. To reappoint the Company's auditor                                        185,776,647  99.09                1,715,177      0.91                     187,491,824       16.42                             4,905,675
 7. To authorise the Audit Committee to determine the auditor's remuneration  176,309,143  94.04                11,179,915     5.96                     187,489,058       16.42%                            4,908,441
 8. To authorise the Directors to allot equity securities                     170,229,487  90.79                17,259,571     9.21                     187,489,058       16.42                             4,908,441
 Special Resolutions                                                          Votes for    % of votes cast for  Votes against  % of votes cast against  Total votes cast  Total votes cast as % of ISC (1)  Votes with-held (2)
 9. To disapply pre-emption provisions                                        156,025,169  89.79                17,751,132     10.21                    173,776,301       15.22                             18,621,198
 10. To reduce the notice period for general meetings                         171,582,521  91.51                15,909,303     8.49                     187,491,824       16.42                             4,905,675

 

(1)        The Company's issued share capital ("ISC") on 28 June 2023,
being the date on which members had to be entered in the register of members
of the Company in order to be entitled to attend and vote at the meeting, was
1,141,999,321 ordinary shares.

(2)        A 'vote withheld' in respect of any resolution is not a vote
in law and is not counted in the calculation of the proportion of the votes
for and against it.

 

A copy of the resolutions passed has been submitted to the National Storage
Mechanism and will shortly be available for inspection at
https://data.fca.org.uk/#/nsm/nationalstoragemechanism
(https://data.fca.org.uk/#/nsm/nationalstoragemechanism) .

 

Enquiries:

 

 Hemogenyx Pharmaceuticals plc                                   https://hemogenyx.com (https://hemogenyx.com/)
 Dr Vladislav Sandler, Chief Executive Officer & Co-Founder      headquarters@hemogenyx.com (mailto:headquarters@hemogenyx.com)
 Peter Redmond, Director                                         peter.redmond@hemogenyx.com (mailto:peter.redmond@hemogenyx.com)

 SP Angel Corporate Finance LLP                                  Tel: +44 (0)20 3470 0470
 Matthew Johnson, Vadim Alexandre, Adam Cowl

 Peterhouse Capital Limited                                      Tel: +44 (0)20 7469 0930
 Lucy Williams, Duncan Vasey, Charles Goodfellow

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RAGNKKBKPBKDAAN